

![]() |
Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study |
|
Authors | ![]() | |
Published in | HIV Medicine. 2002, vol. 3, no. 4, p. 247-253 | |
Abstract | OBJECTIVES: To compare the response to ritonavir (RTV) plus saquinavir (SQV) with single protease inhibitor (PI) therapies among PI-naive HIV-1 infected individuals. METHODS: Response to treatment was analysed according to the intent-to-treat principle in a prospective observational cohort study of 177 patients who between May 1995 and March 2000 started a double PI therapy with RTV and SQV (nonboosting dosages) plus at least one nucleoside reverse transcriptase inhibitor (NRTI) and 2,214 patients with a single PI therapy plus two NRTIs. We used survival analysis and Cox's proportional hazard regression methods. The primary endpoint was the time to a plasma viral load of < 400 copies/mL. Secondary endpoints were taken as a gain in the CD4 count of >100 cells/microL, and change of initial PI for any reason. RESULTS: Baseline characteristics in both treatment groups were balanced. Median follow-up in both groups was 10.4 months. Time to an HIV-1 viral load of < 400 copies/mL and an increase in the CD4 count of >100 x 10(6) cells/L was shorter for RTV plus SQV compared with single PI regimens (log rank test for each endpoint P < 0.05). The adjusted hazard ratios of RTV plus SQV compared with single PI regimens were 1.21 (95% confidence interval 0.99-1.47) for achieving an HIV-1 viral load of < 400 copies/mL, 1.12 (0.88-1.42) for an increase in the CD4 count of > 100 cells/microL, and 0.90 (0.73-1.11) for change of first PI regimen. CONCLUSIONS: Treatment with RTV plus SQV compared with single PI regimens appeared to give similar results for virological or immunological response. | |
Keywords | Adolescent — Adult — Aged — Aged, 80 and over — CD4 Lymphocyte Count — Cohort Studies — Drug Therapy, Combination — Female — Follow-Up Studies — HIV Infections/ drug therapy — HIV Protease Inhibitors/ administration & dosage — Humans — Male — Middle Aged — Prospective Studies — RNA, Viral/blood — Reverse Transcriptase Inhibitors/ administration & dosage — Ritonavir/ administration & dosage — Saquinavir/ administration & dosage — Viral Load | |
Identifiers | PMID: 12444942 | |
Full text | ||
Structures | ||
Citation (ISO format) | BUCHER, H. C. et al. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study. In: HIV Medicine, 2002, vol. 3, n° 4, p. 247-253. https://archive-ouverte.unige.ch/unige:7124 |